Table 1.
MALT (%) | DLBCL (%) | ||
---|---|---|---|
Number of cases | n | 52 | 18 |
Age (yr) | Median | 65 | 65 |
>60 | 35 (67) | 10 (56) | |
<60 | 17 (33) | 8 (44) | |
Sex | Male | 23 (44) | 11 (61) |
Female | 29 (56) | 7 (39) | |
Stage | I/II | 33 (63) | 10 (56) |
III/IV | 19 (37) | 8 (44) | |
B symptoms | Absent | 46 (88) | 14 (78) |
Present | 6 (12) | 4 (22) | |
Autoimmune disease | Pos | 2* (4) | 3** (17) |
Neg | 50 (96) | 15 (83) | |
API2-MALT1 fusion | Pos | 27 (52) | 0 (0) |
Neg | 25 (48) | 18 (100) | |
A. xylosoxidans | Pos | 1 (2) | 2 (11) |
Neg | 51 (98) | 16 (89) | |
Cystic fibrosis | Pos | 0 (0) | 0 (0) |
Neg | 52 (100) | 18 (100) |
MALT: mucosa-associated lymphoid tissue lymphoma, DLBCL: diffuse large B-cell lymphoma, *: Sjögren’s syndrome (n=2), **: Sjögren’s syndrome (n=1) and rheumatoid arthritis (n=2).